

# AMCoR

Asahikawa Medical University Repository <http://amcor.asahikawa-med.ac.jp/>

The Journal of Clinical Endocrinology and Metabolism (2016.7) 101  
(10):3582–3591.

11-Ketotestosterone Is a Major Androgen Produced in Human Gonads.

Yoshitaka Imamichi, Koh-ichi Yuhki, Makoto Orisaka,  
Takeshi Kitano, Kuniaki Mukai, Fumitaka Ushikubi,  
Takanobu Taniguchi, Akihiro Umezawa, Kaoru Miyamoto,  
Takashi Yazawa

1 **11-ketotestosterone is a major androgen produced in human gonads**

2 Yoshitaka Imamichi<sup>1,2</sup>, Koh-ichi Yuhki<sup>1</sup>, Makoto Orisaka<sup>3</sup>, Takeshi Kitano<sup>4</sup>, Kuniaki Mukai<sup>5</sup>,  
3 Fumitaka Ushikubi<sup>1</sup>, Takanobu Taniguchi<sup>6</sup>, Akihiro Umezawa<sup>7</sup>, Kaoru Miyamoto<sup>2</sup>, Takashi  
4 Yazawa<sup>6</sup>

5

6 <sup>1</sup>Department of Pharmacology and <sup>6</sup>Department of Biochemistry, Asahikawa Medical University,  
7 Hokkaido 078-8510, Japan, <sup>2</sup>Department of Biochemistry and <sup>3</sup>Department of Obstetrics and  
8 Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan,

9 <sup>4</sup>Department of Materials and Life Science, Graduate School of Science and Technology,

10 Kumamoto University, Kumamoto 860-8555, Japan, <sup>5</sup>Department of Biochemistry and Medical

11 Education Center, Keio University School of Medicine, Tokyo 160-8582, Japan, <sup>7</sup>Department of

12 Reproduction, National Research Institute for Child Health and Development, Tokyo 157-8535,

13 Japan

14

15 **Abbreviated title:** The production of 11-KT in human gonads

16 **Key terms:** Androgen, 11-ketotestosterone, HSD11B2, CYP11B1, aromatase

17 **Word count:** 3553

18 **Numbers of figures and tables:** 6 figures

19

20 *Address all correspondence and person to whom to requests reprints should be addressed:*

21 Takashi Yazawa, PhD

22 Department of Biochemistry,

23 Asahikawa Medical University,

24 Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan

25 Phone: +81-166-68-2342

26 Fax: +81-166-68-2349

27 e-mail: [yazawa@asahikawa-med.ac.jp](mailto:yazawa@asahikawa-med.ac.jp)

28

29 **Disclosure statement;** all authors have nothing to disclose.

30

31 **Context:** 11-ketotestosterone (11-KT) is a novel class of active androgen. However, the detail of  
32 its synthesis remains unknown for humans.

33

34 **Objective:** The objective of this study was to clarify the production and properties of 11-KT in  
35 human.

36

37 **Design, Participants and Methods:** We investigated the 11-KT production in granulosa cell  
38 tumor-derived KGN cells during their differentiation by the introduction of steroidogenic factor-  
39 1. Expression of CYP11B1 and HSD11B2 (key enzymes involved in the synthesis of 11-KT from  
40 testosterone) were investigated in human gonads. The production of 11-KT was also investigated  
41 in human Leydig cells. Plasma concentrations of testosterone and 11-KT were measured in 10  
42 women and 10 men of reproductive age. Investigation of its properties was performed using breast  
43 cancer-derived MCF-7 cells.

44

45 **Results:** 11-KT production was induced in KGN cells during differentiation. CYP11B1 and  
46 HSD11B2 were detected in human testicular Leydig cells and ovarian theca cells. Leydig cells  
47 produced 11-KT, and relatively high levels of plasma 11-KT were measured in both men and  
48 women. There was no sexual dimorphism in the plasma levels of 11-KT, even though testosterone

49 levels were more than 20-times higher in men than in women. It is noteworthy that the levels of  
50 testosterone and 11-KT were similar in women. In a luciferase reporter system, 11-KT activated  
51 human androgen receptor (AR)-mediated transactivation in KGN cells. Conversely, 11-KT did  
52 not activate estrogen receptor-mediated transactivation in aromatase-expressed MCF-7 cells,  
53 whereas testosterone did following conversion to estrogen. Consistent with observations in the  
54 reporter assays, 11-KT did not affect the estrogen/estrogen receptor-mediated cell proliferation of  
55 MCF-7 cells. Furthermore, it significantly inhibited cell proliferation when AR was transfected  
56 into MCF-7 cells.

57

58 **Conclusions:** The current study indicates that 11-KT is produced in the gonads and represents a  
59 major androgen in human. It can potentially serve as a non-aromatizable androgen.

## 60 **Introduction**

61 Androgens are sex steroid hormones that play a role in various physiological processes via  
62 pathways involving the androgen receptor (AR) (1). Testosterone is the most important androgen,  
63 and is produced from cholesterol in the gonads in a series of steps catalyzed by steroid P450  
64 hydroxylases and hydroxysteroid dehydrogenase (2). Although testosterone itself strongly  
65 activates AR-mediated transactivation, it is also converted to a more potent androgen, 5 $\alpha$ -  
66 dihydrotestosterone (DHT), by 5 $\alpha$ -reductase in male peripheral tissues. The androgen/AR  
67 pathway is essential for male physiology, reproduction and the development of sexual  
68 characteristics (3). Although androgens are traditionally viewed as male hormones, androgen/AR  
69 signaling is also important for optimal female reproduction and physiology (4,5). Because  
70 androgen levels reduce with aging before menopause, postmenopausal women suffer various  
71 symptoms by androgen insufficiency (5,6). On the other hand, androgen excess in women results  
72 in a variety of pathological conditions, including polycystic ovary syndrome (PCOS) and  
73 idiopathic **hirsutism** (7). Therefore, proper androgen signaling is important for the health of  
74 women. In addition to androgenic actions, testosterone is also a precursor for estrogen. Aromatase  
75 (CYP19A1) converts testosterone into the most potent estrogen, 17 $\beta$ -estradiol (E<sub>2</sub>). It activates  
76 two subtypes of estrogen receptors (ER), ER $\alpha$  and  $\beta$ , the expression patterns of which are tissue  
77 and cell specific. Adrenal gland also produces testosterone and high concentrations of weak

78 androgens, such as dehydroepiandrosterone (DHEA), DHEA sulfate, androstenedione, 11 $\beta$ -  
79 hydroxyandrostenedione (11-OHA), and 11 $\beta$ -hydroxytestosterone (11-OHT), which are also  
80 precursors for stronger androgens in target tissues (8-10). In previous studies, we and others have  
81 reported that 11-ketotestosterone (11-KT, International Union of Pure and Applied  
82 Chemistry name is 17-Hydroxyandrost-4-ene-3,11-dione) is another class of active  
83 androgen that can be converted from testosterone and other weaker precursors (9-11).

84 CYP11B1 and HSD11B2 play important roles in the 11-KT synthesis from testosterone (10,11).

85 It is well-known that these enzymes are involved in glucocorticoid synthesis and metabolism.

86 CYP11B1 catalyzes the final step of glucocorticoid production in the adrenal gland (12,13), while

87 HSD11B2 converts active glucocorticoids into inactive 11-ketosteroid forms, which are

88 abundantly expressed in the kidney and placenta (14). We have demonstrated that Cyp11b1 and

89 Hsd11b2 are expressed in murine gonads and are involved in gonadotropin-induced 11-KT

90 production (11). 11-KT can strongly activate mammalian AR-mediated transactivation. It was

91 also reported that 11-KT can be detectable in human blood samples (9). Thus, it is conceivable

92 that 11-KT is common androgen in mammals, although the detail of its synthesis remains

93 unknown. In the present study, we evaluated the production and properties of 11-KT in humans.

94

95 **Materials and Methods**

96 **Cell culture and transfection**

97 Human ovarian granulosa cell tumor-derived KGN cells (kindly donated by Dr. Toshihiko  
98 Yanase, University of Fukuoka, Fukuoka, Japan) and MCF-7 cells were cultured in  
99 DMEM/Ham's F-12 medium supplemented with 10% fetal bovine serum (FBS). Human  
100 adrenocortical tumor-derived H295R cells were cultured in Opti-MEM supplemented with 2%  
101 Nu-serum IV (BD Biosciences, Franklin Lakes, NJ, USA). Human Leydig cells were purchased  
102 from ScienCell Research Laboratories (Carlsbad, CA), which are sourced within the USA under  
103 protocols that have obtained Institutional Review Board (IRB) approval. They were cultured in  
104 Leydig Cell Medium (ScienCell Research Laboratories). The research protocol using human  
105 materials was approved at the ethical committee of Asahikawa Medical University. H295R cells  
106 were transfected using an Amaxa Nucleofector Technology system (Lonza, Cologne, Germany)  
107 as described (15). KGN and MCF-7 cells were transfected using Lipofectamine LTX reagent (Life  
108 Technologies, Inc., Carlsbad, CA, USA) and HilyMax (Dojindo Laboratories, Kumamoto, Japan).  
109 One day before transfection, the cells were seeded on 24-well plates and cultured with phenol  
110 red-free medium supplemented with 10% charcoal/dextran stripped (CD)-FBS. After 24 h  
111 transfection, the cells were treated with vehicle (EtOH) or steroid hormones for 24 h. Luciferase  
112 assays were performed as described previously (15,16). Each data point represents the mean of at  
113 least four independent experiments.



114

## 115 **Adenovirus production and infection**

116 Adenovirus vectors for LacZ, GFP, and Steroidogenic factor-1 (SF-1) were prepared using the  
117 Adeno-X Expression System 1 (Takara, Shiga, Japan), following the manufacturer's instructions  
118 as described (16). Using these vectors, replication-defective recombinant adenoviruses were  
119 propagated and titered in HEK 293 cells. Then, they were used to infect KGN cells at MOI 10.  
120 **GFP-expressing adenovirus used as a transduction control during infection. Transduction**  
121 **efficiency and optimal concentrations of virus were determined by investigating GFP expression**  
122 **using fluorescent microscopy.** At 48 h post-infection, cells were processed for RNA or protein  
123 extraction.

124

## 125 **DNA microarray**

126 Expression analysis by DNA microarray has been described elsewhere (17). Briefly, labeled  
127 cRNA was prepared from KGN cells with adenovirus-mediated expression of LacZ, GFP, or SF-  
128 1. After fragmentation of cRNA, hybridization was performed with a human U133 Plus 2.0  
129 Affymetrix GeneChip (Affymetrix, Santa Clara, CA, USA). The arrays were scanned using a  
130 Gene-Array scanner and the data were generated by Affymetrix Microarray Suite 4.0. Data were  
131 analyzed using Subio Platform software (<http://www.subio.jp/products/platform>).

132

### 133 **RT-PCR and quantitative (Q)-PCR**

134 Total RNA from the cultured cells was extracted using TriPure Isolation Reagent (Roche,  
135 Carlsbad, CA, USA). Total RNA from human testis, ovary, adrenal, liver, and kidney was  
136 purchased from Takara Bio Inc. (Shiga, Japan) and Biochain Institute Inc. (Newark, CA). RT-  
137 PCR and Q-PCR was performed as described (16,18). The RT-PCR products were  
138 electrophoresed on a 1.5% (w/v) agarose gel, and the resulting bands were visualized by staining  
139 with ethidium bromide. In Q-PCR, each gene expression was measured by real-time PCR and  
140 normalized with  $\beta$ -actin expression. The primers used for PCR are described in Supplemental  
141 Table1. The primers used for other genes were as described (16,18).

142

### 143 **Western blotting analysis**

144 Extraction of total proteins from cultured cells and subsequent quantification were conducted  
145 as described previously (16). Protein extract samples from each human tissue were purchased  
146 from BioChain Institute Inc. (Hayward, CA, USA). Ovarian tissue donors were able to donate  
147 healthy organs and were of reproductive age (aged 30-34 years). Each tissue sample was  
148 collected under strict IRB ethical consenting practices. Equal amounts of protein (20  $\mu$ g) were  
149 resolved using 12.5% SDS-PAGE and transferred to polyvinylidene difluoride membranes.

150 Western blot analyses of HSD11B2, CYP11B1, AR,  $\beta$ -actin and GAPDH were performed with  
151 antibodies directed against HSD11B2 (H-145, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,  
152 USA), CYP11B1 (13), AR (N-20, Santa Cruz Biotechnology, Inc.),  $\beta$ -actin (C4, Santa Cruz  
153 Biotechnology, Inc.) and GAPDH (6C5, Santa Cruz Biotechnology, Inc.), respectively.  
154 Enhanced chemiluminescence western blot reagents (Bio-Rad Laboratories Inc., Hercules, CA,  
155 USA) were used for detection.

156

### 157 **Plasmids**

158 The pcDNA3 expressing HSD11B2 was generated by cloning the open reading frame of  
159 HSD11B2 into a pcDNA3 vector (Invitrogen, Carlsbad, CA). A Slp-ARU/Luc reporter and  
160 pQCXIP/human AR were prepared as described (11,19). The ERE/Luc was constructed by  
161 inserting the oligonucleotides into a pGL4.24 plasmid (Promega Corp., Madison, WI, USA).

162

### 163 **Immunohistochemistry**

164 Immunohistochemistry was performed as described previously (11,19). Sections of human testis  
165 (from men aged 23 and 50 years) and ovary (from woman aged 19 and 34 years) were purchased  
166 from US Biomax Inc. (Rockville, MD) and Biochain Institute Inc. (Newark, CA). Sections were  
167 subjected to the antigen retrieval technique with Dako Target Retrieval Solution, pH 9 (Dako

168 Denmark A/S, Glostrup, Denmark) and treated with anti-CYP11B1 (13) and anti-HSD11B2 (20).  
169 They were then developed using a Vectastain Elite ABC kit (Vector Laboratories, Burlingame,  
170 CA).

171

## 172 **Human blood samples**

173 Blood samples were collected in collection tubes containing heparin from the median cubital  
174 vein of two healthy women volunteers at University of Fukui Hospital in 2007. Plasma was  
175 separated by centrifugation at 1000 x g for 5 min. Other plasma samples were purchased from  
176 AllCells (Emeryville, CA) and ProMedDX (Norton, MA). All plasma samples were collected  
177 under IRB approved collection protocols and subject informed consent. The donors were 10 men  
178 (aged  $32.1 \pm 7.8$  year) and 10 women (aged  $31.7 \pm 6.0$  years). Plasma samples were stored at -  
179 80 °C until assays. The research protocol for using human materials was approved by the Ethics  
180 Committee of the University of Fukui.

181

## 182 **Measurements by enzyme immunoassays (EIA) and liquid chromatography-tandem mass** 183 **spectrometry (LC-MS/MS)**

184 Concentrations of testosterone, 11-KT and E2 in culture media of KGN, H295R and human  
185 Leydig cells were determined by competitive EIA (11,19). Each sample was diluted with EIA

186 buffer, and analyzed using progesterone, testosterone, 11-KT and E<sub>2</sub> EIA Kit (Cayman Chemical  
187 Company, Ann Arbor, MI) following the manufacturer's instructions in a microplate reader  
188 (Molecular Device SpectraMax M5; Molecular Device, LLC, Sunnyvale, CA). **On the other hand,**  
189 **concentrations of steroid hormones in human plasma were measured by LC-MS/MS for optimal**  
190 **quantification of the clinical samples. Processing of human plasma samples and quantification of**  
191 **testosterone, 11-KT and E<sub>2</sub> by LC-MS/MS are based on methods as described previously (9).**

192

### 193 **Retrovirus preparation and infection**

194 The Phoenix packaging cell line was transiently transfected with the retroviral  
195 plasmids using the FuGENE 6 reagent (Promega). The supernatant was concentrated  
196 by centrifugation. The virus solution was stored at -80 °C until use. MCF-7 cells  
197 were infected with the retrovirus in the presence of 8 µg/mL Polybrene (Sigma-  
198 Aldrich) for 48 h. The cells were then replated and selected using puromycin.

199

### 200 **Proliferation assay**

201 MCF-7 cells or AR-introduced cells were seeded with DMEM/F-12 supplemented with 10% or  
202 2% CD-FBS at 1×10<sup>3</sup> cells/well in 96-well plates. At 24 h after seeding, the cells were treated  
203 with the media containing various concentrations of DHT, testosterone, 11-KT, or E<sub>2</sub>. Six days

204 (parental cells) or nine days (AR-introduced cells) after incubation, cell proliferation was  
205 evaluated using a CellTiter 96 Aqueous One Solution Kit (Promega) following the manufacturer's  
206 instructions. To evaluate the effect of an aromatase inhibitor, fadrozole (Sigma, St, Louis, MO)  
207 or an estrogen receptor antagonist, fulvestrant (Sigma), on the growth of MCF-7 cells, a  
208 proliferation assay was performed with or without these agents.

209

## 210 **Statistics**

211 Data are presented as the mean  $\pm$  SEM. Differences between groups ( $P < 0.05$ ) were assessed  
212 by the Student's *t*-test or one-way ANOVA followed by Tukey's multiple comparison tests using  
213 EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) (21),  
214 which is a graphical user interface for R (The R Foundation for Statistical  
215 Computing, Vienna, Austria).

216

## 217 **Results**

### 218 **HSD11B2 is induced by SF-1 and involved in the 11-KT production**

219 Human ovarian granulosa cell tumor-derived KGN cells have low steroidogenic capacity under  
220 basal conditions. However, they can be transformed to produce a range of steroid hormones by  
221 infection with an adenovirus expressing SF-1 and its co-activator (16). To examine changes in

222 gene expression in this transformation, we used a DNA microarray with GFP- or SF-1-introduced  
223 KGN cells. SF-1 introduction induced a number of genes, including steroidogenic enzymes such  
224 as CYP11A1, HSD3B2, CYP17A1, and CYP19A1 (Supplemental Table 2), which are known SF-  
225 1 targets (22). In addition to these genes, HSD11B2 was a strong SF-1-inducible candidate gene  
226 (Supplemental Table 2) and was almost undetectable in GFP-introduced cells (Figure 1 A and B).  
227 Consistent with DNA microarray data, Q-PCR and immunoblotting analyses revealed that  
228 introduction of SF-1 strongly induced HSD11B2 mRNA and proteins (Figure 1 A and B). In  
229 previous studies, it was demonstrated that **HSD11B2** is involved in 11-KT production from  
230 testosterone with **CYP11B1** (Supplemental Figure 1) in murine gonads (11,19) or from adrenal  
231 androgens by *in vitro* analysis (10). The DNA microarray analyses suggest that CYP11B1 is an  
232 SF-1-inducible gene, as well as other steroidogenic genes that are involved in testosterone and E<sub>2</sub>  
233 synthesis (Figure 1C, Supplemental Table 2, Supplemental Figure 1). In fact, the introduction of  
234 SF-1 induced not only the production of testosterone and E<sub>2</sub>, but also the CYP11B1 expression  
235 and 11-KT production (Figure 1 C and D).

236 To verify the role of HSD11B2 during 11-KT production in human steroidogenic cells, it was  
237 ectopically expressed in human adrenocortical H295R cells. H295R cells expressed CYP11B1  
238 and other steroidogenic enzymes for testosterone synthesis (Supplemental Figure 2), whereas  
239 endogenous HSD11B2 was undetectable (Figure 2A). Even though H295R cells produce

240 testosterone at relatively high levels, its conversion to 11-KT was marginal (Figure 2 C and D).  
241 Transient transfection of the HSD11B2 expression vector (Fig. 2B) markedly increased 11-KT  
242 production compared with the control group (Figure 2D), whereas testosterone concentrations  
243 were similar in both groups (Figure 2C). These results indicate that the expression of human  
244 HSD11B2 could be an important factor for the production of 11-KT in steroidogenic cells.

245

#### 246 **11-KT is produced in gonads and is one of the major androgens in human**

247 To elucidate the 11-KT synthesis pathway, we investigated the expression of CYP11B1 and  
248 HSD11B2 in human gonads (Figure 3 A and B). Q-PCR and western blot analyses showed that  
249 both genes were detectable in the testis and ovary at the mRNA and protein levels (Figure 3 A and  
250 B). Immunohistochemical analysis showed that both proteins are localized on testicular Leydig  
251 cells and ovarian theca cells, even though HSD11B2 is also detectable in some populations of  
252 ovarian granulosa cells (Fig. 3C). These results strongly suggest that 11-KT is produced in  
253 testicular Leydig cells and ovarian theca cells. To confirm this hypothesis, we investigated the  
254 production of 11-KT in human Leydig cells. In support of the immunohistochemical analyses,  
255 Leydig cells expressed CYP11B1 and HSD11B2 genes (Supplemental Figure 3A). They can  
256 produce progesterone, testosterone and 11-KT under basal conditions (Fig. 3D, Supplemental  
257 Figure 3B). cAMP-treatment moderately increased the production of these steroid hormones.



258 Then, we measured plasma concentrations of 11-KT, testosterone and E<sub>2</sub> in both sexes (Figure  
259 3 E-G). Testosterone levels in men were about 22-fold higher than those in women, whereas 11-  
260 KT levels were similar between the sexes (Figure 3 E and F). It is noteworthy in women that 11-  
261 KT concentrations were similar to testosterone concentrations and about 5-fold higher than E<sub>2</sub>  
262 concentrations (Figure 3H). Human AR-mediated transactivation was significantly increased by  
263 11-KT at concentrations >10<sup>-9</sup> M in KGN cells (Figure 4). This level is lower than that for the  
264 induction by other androgens, although transactivation was increased to similar levels by DHT  
265 and testosterone at 10<sup>-8</sup> and 10<sup>-7</sup> M, respectively. **These results suggest the possibility that 11-KT**  
266 **plays some roles in human as one of the major androgens.**

267

#### 268 **11-KT is not convertible to estrogenic hormones**

269 In female individuals, testosterone acts as both an androgen and a precursor for estrogen. To  
270 determine whether 11-KT is a precursor for estrogen, we performed a luciferase assay using a  
271 reporter plasmid containing the estrogen response element (ERE) in human breast cancer derived  
272 MCF-7 cells, which endogenously express aromatase and ER $\alpha$ . In contrast to E<sub>2</sub>, androgens had  
273 no effect on luciferase activity at lower concentrations (10<sup>-11</sup> and 10<sup>-10</sup> M) (Figure 5A). However,  
274 testosterone activated ER-dependent transcription at high concentrations and at 10<sup>-7</sup> M  
275 testosterone was effective as E<sub>2</sub>. This activity was completely suppressed by an aromatase

276 inhibitor, fadrozole (Figure 5B). DHT weakly activated ER-mediated transactivation in an  
277 aromatase-independent manner at  $10^{-7}$  M. In contrast, 11-KT had no effect on ER-mediated  
278 transactivation, even at  $10^{-6}$  M (Figure 5A, data not shown). These results indicate that 11-KT is  
279 a non-aromatizable androgen, and does not convert to a compound that activates ER-mediated  
280 transactivation.

281 Then, we assessed the effect of 11-KT on cell proliferation in MCF-7 cells. The proliferation of  
282 MCF-7 cells is highly dependent on estrogens. Consistent with previous studies, MCF-7 cells  
283 were increased by  $>10^{-11}$  M  $E_2$  (Figure 6A). In support of the reporter assays result, testosterone  
284 significantly stimulated cell proliferation at higher concentrations (Figure 6A), and fadrozole and  
285 the ER antagonist fulvestrant completely inhibited testosterone-induced cell proliferation (Figure  
286 6 B and C). Conversely, 11-KT had no effect on cell growth at any concentration, similar to DHT.  
287 These results strongly suggest that 11-KT acts as a stable androgen in both AR- and aromatase-  
288 positive cells. To further test this hypothesis, AR was stably transfected into MCF-7 cells (Figure  
289 6D) and we measured the AR-mediated growth inhibition of each androgen. Consistent with  
290 previous reports (23), DHT strongly suppressed cell proliferation in AR-introduced MCF-7 cells  
291 (Figure 6E). Similarly, 11-KT also inhibited proliferation, though to a lesser extent than DHT. In  
292 contrast, testosterone did not significantly inhibit cell growth.

293

294 **Discussion**

295 11-KT is one of the active androgens, which was originally characterized as a teleost-specific  
296 hormone. However, we and others have since noted that it is also present in mammals (9-11).  
297 Here, we found evidence that 11-KT is produced in human gonads and is one of the major  
298 androgens. It can potentially act as a non-aromatizable androgen. Testicular Leydig cells and  
299 ovarian theca cells expressed the enzymes for producing 11-KT from testosterone, CYP11B1 and  
300 HSD11B2. In fact, Leydig cells produced 11-KT, autonomously.

301 HSD11B2 protects mineralocorticoid receptor (MR) from glucocorticoid by inactivating cortisol  
302 to corticosterone in aldosterone-sensitive tissues (14). The gonads are target organs for  
303 mineralocorticoids, which express MR (24,25). Mineralocorticoids can stimulate the production  
304 of testosterone and progesterone in testicular Leydig cells (24) and ovarian granulosa cells (26),  
305 respectively. Conversely, glucocorticoids inhibit testicular and ovarian steroidogenesis (27).  
306 Because HSD11B2 proteins are expressed in these cells, it is reasonable to assume that gonadal  
307 HSD11B2 plays a role in the protection of steroidogenic cells from the adverse effects of  
308 glucocorticoids. In addition to this classical role, the involvement of HSD11B2 in 11-KT  
309 production in Leydig cells and theca cells may represent another important role (10,11). Our  
310 results strongly suggest that the gonads are main organs for 11-KT production in humans by the  
311 expression of HSD11B2.

312 In mammals, CYP11B1 is thought to be an adrenal-specific enzyme that is essential for the  
313 final step of glucocorticoid synthesis (12). However, it is also expressed in the testicular Leydig  
314 cells and ovarian theca cells to a lesser extent. There is also evidence that CYP21 is expressed in  
315 the gonads (25,28). Thus, a contribution of gonadal CYP11B1 to local glucocorticoid synthesis  
316 cannot be ruled out, although there are no studies documenting high levels of cortisol in the  
317 gonads. Rather, it is often reported that cortisol levels are lower in ovarian follicular fluid (FF)  
318 than in the blood (29,30). Therefore, it is conceivable that the production of precursors for 11-KT  
319 could be one of the most important functions of CYP11B1 in the gonads. Indeed, testosterone and  
320 androstenedione are efficiently converted to the 11-KT precursors (11-OHT and 11-OHA) by  
321 ectopic expression of human CYP11B1 with ferredoxin in COS-1 cells. (10). Consistent with this  
322 *in vitro* study, high levels of these steroids are produced in the CYP11B1-abundant adrenal gland,  
323 even though they are rarely converted to 11-keto products by low-level expression of HSD11B2  
324 in the adrenal. However, it is probable that adrenal-derived 11-OHT and 11-OHA could be another  
325 sources of human 11-KT by the conversion in HSD11B2 expressing organs, including gonads.

326 There was no sexual dimorphism of human plasma 11-KT levels, even though testosterone levels  
327 were much higher in men. Similar phenomena were also observed in rodents (11). This indicates  
328 that the dominance of 11-KT production in female is conserved between rodents and humans. In  
329 mice, the abundant expression of ovarian HSD11B2 is likely responsible for this dominance (11).

330 In addition, the testicular expression of Hsd11b1 was much higher than in the ovary (11). Because  
331 this 11 $\beta$ -HSD isoform preferentially catalyzes the reduction of 11-ketosteroid (31), the difference  
332 in its expression between sexes also results in ovarian dominance of 11-KT production. Such  
333 sexual differences in the expression of both HSD11B1 (unpublished data) and HSD11B2 were  
334 unclear in human gonads. In addition to the level of expression, the activity of 11 $\beta$ -HSD enzymes  
335 is regulated by a number of factors (32,33). It is interesting that human ovarian FF contains the  
336 selective inhibitor for HSD11B1 (34). Additionally, it was also reported that ovarian FF contains  
337 much higher concentrations of 11-OHA than plasma levels, which is converted from cortisol in  
338 granulosa cells (35). This might be another pathway for ovarian 11-KT production. Further studies  
339 are needed to evaluate the sexual dimorphism of 11-KT production in humans.

340 DHT, testosterone, and 11-KT can strongly activate AR-mediated transactivation, even though  
341 there are some differences, especially at lower levels. Testosterone acts not only as an androgen,  
342 but also as a precursor for estrogens. It can be converted to E<sub>2</sub> in aromatase-expressing cells, and  
343 induces estrogen-dependent phenomena. Conversely, it is probable that 11-KT is not converted to  
344 estrogen by aromatase. Although DHT is also a non-aromatizable androgen, it can be converted  
345 to 3 $\beta$ -diol by HSD17B7, which can bind to ERs (36). Therefore, 11-KT likely represents  
346 extremely difficult androgen to convert to an estrogenic steroid. In addition, plasma 11-KT levels  
347 are similar to testosterone levels in women at reproductive age, and in menopausal women (9).

348 Thus, it is possible that 11-KT play important roles in female, especially in AR- and aromatase-  
349 expressing tissues such as ovary and breast. In a previous study, we demonstrated using mice that  
350 testosterone and 11-KT are elevated at ovulatory LH/hCG-stimulation, and are involved in the  
351 expression of ovulation-related genes, such as Cyclooxygenase-2 and Amphiregulin, in granulosa  
352 cells (19). This issue could be a subject of further investigation in human, because preovulatory  
353 follicles express CYP19A1 gene at high levels (37).

354 In summary, we demonstrated that 11-KT is a major androgen and produced in gonads. Because  
355 androgens are essential for reproduction and physiology, their excess and deficiency often induce  
356 pathogenesis. Then, it is possible that 11-KT could be responsible for, and the novel target of  
357 therapies against, such diseases. In addition, it might provide novel insights for elucidating  
358 ambiguous AR-mediated phenomena.

359

### 360 **Acknowledgments**

361 We are grateful to Dr. T. Yanase for providing reagents. This work was supported in part by JSPS  
362 KAKENHI Grant Number 23590329 (to T.T., Grant-in-Aid for Scientific Research (C)),  
363 15K10654 (to T.Y., Grant-in-Aid for Scientific Research (C)) and 25861482 (to Y.I., Grant-in-  
364 Aid for Young Scientist (B)) granted by Japan Society for the Promotion of Science, the Smoking  
365 Research Foundation (to T.T.), Yamaguchi Endocrine Research Foundation (to T.Y.) and the fund

366 for Asahikawa Medical University Creative Research Foundation (to T.Y).

367

368 **References**

369 1. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. *Endocr*  
370 *Rev* 1987; 8:1-28.

371 2. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human  
372 steroidogenesis and its disorders. *Endocr Rev* 2011; 32:81-151.

373 3. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS.  
374 Androgen receptor defects: historical, clinical, and molecular perspectives. *Endocr*  
375 *Rev* 1995; 16:271-321.

376 4. Lebbe M, Woodruff TK. Involvement of androgens in ovarian health and disease. *Mol*  
377 *Hum Reprod* 2013; 19:828-837.

378 5. Rivera-Woll LM, Papalia M, Davis SR, Burger HG. Androgen insufficiency in women:  
379 diagnostic and therapeutic implications. *Hum Reprod Update* 2004; 10:421-432.

380 6. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein  
381 I, Guay A, Leiblum S, Lobo R, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J,  
382 Simpson E, Shifren J, Spark R, Traish A. Female androgen insufficiency: the  
383 Princeton consensus statement on definition, classification, and assessment. *Fertil*

- 384 Steril 2002; 77:660-665.
- 385 7. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor  
386 K, Boots LR. Androgen excess in women: experience with over 1000 consecutive  
387 patients. J Clin Endocrinol Metab 2004; 89:453-462.
- 388 8. Cohn GL, Mulrow PJ. Androgen release and synthesis in vitro by human adult  
389 adrenal glands. J Clin Invest 1963; 42:64-78.
- 390 9. Rege J, Nakamura Y, Satoh F, Morimoto R, Kennedy MR, Layman LC, Honma S,  
391 Sasano H, Rainey WE. Liquid chromatography-tandem mass spectrometry analysis  
392 of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J Clin  
393 Endocrinol Metab 2013; 98:1182-1188.
- 394 10. Swart AC, Schloms L, Storbeck KH, Bloem LM, Toit T, Quanson JL, Rainey WE,  
395 Swart P. 11beta-hydroxyandrostenedione, the product of androstenedione  
396 metabolism in the adrenal, is metabolized in LNCaP cells by 5alpha-reductase  
397 yielding 11beta-hydroxy-5alpha-androstanedione. J Steroid Biochem Mol Biol 2013;  
398 138:132-142.
- 399 11. Yazawa T, Uesaka M, Inaoka Y, Mizutani T, Sekiguchi T, Kajitani T, Kitano T,  
400 Umezawa A, Miyamoto K. Cyp11b1 is induced in the murine gonad by luteinizing  
401 hormone/human chorionic gonadotropin and involved in the production of 11-



402 ketotestosterone, a major fish androgen: conservation and evolution of the androgen  
403 metabolic pathway. *Endocrinology* 2008; 149:1786-1792.

404 **12.** Kawamoto T, Mitsuuchi Y, Toda K, Yokoyama Y, Miyahara K, Miura S, Ohnishi T,  
405 Ichikawa Y, Nakao K, Imura H, et al. Role of steroid 11 beta-hydroxylase and steroid  
406 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in  
407 humans. *Proc Natl Acad Sci U S A* 1992; 89:1458-1462.

408 **13.** Nishimoto K, Nakagawa K, Li D, Kosaka T, Oya M, Mikami S, Shibata H, Itoh H,  
409 Mitani F, Yamazaki T, Ogishima T, Suematsu M, Mukai K. Adrenocortical zonation  
410 in humans under normal and pathological conditions. *J Clin Endocrinol Metab* 2010;  
411 95:2296-2305.

412 **14.** White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the  
413 syndrome of apparent mineralocorticoid excess. *Endocr Rev* 1997; 18:135-156.

414 **15.** Imamichi Y, Mizutani T, Ju Y, Matsumura T, Kawabe S, Kanno M, Yazawa T,  
415 Miyamoto K. Transcriptional regulation of human ferredoxin reductase through an  
416 intronic enhancer in steroidogenic cells. *Biochim Biophys Acta* 2014; 1839:33-42.

417 **16.** Yazawa T, Inaoka Y, Okada R, Mizutani T, Yamazaki Y, Usami Y, Kuribayashi M,  
418 Orisaka M, Umezawa A, Miyamoto K. PPAR-gamma coactivator-1alpha regulates  
419 progesterone production in ovarian granulosa cells with SF-1 and LRH-1. *Mol*

420 Endocrinol 2010; 24:485-496.

421 **17.** Ju Y, Mizutani T, Imamichi Y, Yazawa T, Matsumura T, Kawabe S, Kanno M,  
422 Umezawa A, Kangawa K, Miyamoto K. Nuclear receptor 5A (NR5A) family regulates  
423 5-aminolevulinic acid synthase 1 (ALAS1) gene expression in steroidogenic cells.  
424 Endocrinology 2012; 153:5522-5534.

425 **18.** Yazawa T, Mizutani T, Yamada K, Kawata H, Sekiguchi T, Yoshino M, Kajitani T,  
426 Shou Z, Umezawa A, Miyamoto K. Differentiation of adult stem cells derived from  
427 bone marrow stroma into Leydig or adrenocortical cells. Endocrinology 2006;  
428 147:4104-4111.

429 **19.** Yazawa T, Kawabe S, Kanno M, Mizutani T, Imamichi Y, Ju Y, Matsumura T,  
430 Yamazaki Y, Usami Y, Kuribayashi M, Shimada M, Kitano T, Umezawa A, Miyamoto  
431 K. Androgen/androgen receptor pathway regulates expression of the genes for  
432 cyclooxygenase-2 and amphiregulin in periovulatory granulosa cells. Mol Cell  
433 Endocrinol 2013; 369:42-51.

434 **20.** Nishimoto K, Rigsby CS, Wang T, Mukai K, Gomez-Sanchez CE, Rainey WE, Seki T.  
435 Transcriptome analysis reveals differentially expressed transcripts in rat adrenal  
436 zona glomerulosa and zona fasciculata. Endocrinology 2012; 153:1755-1763.

437 **21.** Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical

- 438 statistics. *Bone Marrow Transplant* 2013; 48:452-458.
- 439 **22.** Yazawa T, Imamichi Y, Miyamoto K, Khan M, Uwada J, Umezawa A, Taniguchi T.  
440 Regulation of Steroidogenesis, Development and Cell Differentiation by  
441 Steroidogenic Factor-1 and Liver Receptor Homolog-1. *Zoological Science* 2015;  
442 32:323-330.
- 443 **23.** Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M. Breast  
444 cancer: from estrogen to androgen receptor. *Mol Cell Endocrinol* 2002; 193:121-128.
- 445 **24.** Ge RS, Dong Q, Sottas CM, Latif SA, Morris DJ, Hardy MP. Stimulation of  
446 testosterone production in rat Leydig cells by aldosterone is mineralocorticoid  
447 receptor mediated. *Mol Cell Endocrinol* 2005; 243:35-42.
- 448 **25.** Amin M, Simerman A, Cho M, Singh P, Briton-Jones C, Hill D, Grogan T, Elashoff D,  
449 Clarke NJ, Chazenbalk GD, Dumesic DA. 21-Hydroxylase-derived steroids in follicles  
450 of nonobese women undergoing ovarian stimulation for in vitro fertilization (IVF)  
451 positively correlate with lipid content of luteinized granulosa cells (LGCs) as a source  
452 of cholesterol for steroid synthesis. *J Clin Endocrinol Metab* 2014; 99:1299-1306.
- 453 **26.** Fru KN, VandeVoort CA, Chaffin CL. Mineralocorticoid synthesis during the  
454 periovulatory interval in macaques. *Biol Reprod* 2006; 75:568-574.
- 455 **27.** Whirledge S, Cidlowski JA. Glucocorticoids, stress, and fertility. *Minerva Endocrinol*

- 456 2010; 35:109-125.
- 457 **28.** Hu L, Monteiro A, Johnston H, King P, O'Shaughnessy PJ. Expression of Cyp21a1  
458 and Cyp11b1 in the fetal mouse testis. *Reproduction* 2007; 134:585-591.
- 459 **29.** Lewicka S, von Hagens C, Hettinger U, Grunwald K, Vecsei P, Runnebaum B, Rabe  
460 T. Cortisol and cortisone in human follicular fluid and serum and the outcome of IVF  
461 treatment. *Hum Reprod* 2003; 18:1613-1617.
- 462 **30.** von Wolff M, Schneider S, Kollmann Z, Weiss B, Bersinger NA. Exogenous  
463 gonadotropins do not increase the blood-follicular transportation capacity of extra-  
464 ovarian hormones such as prolactin and cortisol. *Reprod Biol Endocrinol* 2013; 11:87.
- 465 **31.** Gathercole LL, Lavery GG, Morgan SA, Cooper MS, Sinclair AJ, Tomlinson JW,  
466 Stewart PM. 11beta-Hydroxysteroid dehydrogenase 1: translational and therapeutic  
467 aspects. *Endocr Rev* 2013; 34:525-555.
- 468 **32.** Quinkler M, Johanssen S, Grossmann C, Bahr V, Muller M, Oelkers W, Diederich S.  
469 Progesterone metabolism in the human kidney and inhibition of 11beta-  
470 hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. *J Clin*  
471 *Endocrinol Metab* 1999; 84:4165-4171.
- 472 **33.** Kossintseva I, Wong S, Johnstone E, Guilbert L, Olson DM, Mitchell BF.  
473 Proinflammatory cytokines inhibit human placental 11beta-hydroxysteroid

474 dehydrogenase type 2 activity through Ca<sup>2+</sup> and cAMP pathways. Am J Physiol  
475 Endocrinol Metab 2006; 290:E282-288.

476 **34.** Thurston LM, Norgate DP, Jonas KC, Chandras C, Kloosterboer HJ, Cooke BA,  
477 Michael AE. Ovarian modulators of 11beta-hydroxysteroid dehydrogenase  
478 (11betaHSD) activity in follicular fluid from gonadotrophin-stimulated assisted  
479 conception cycles. Reproduction 2002; 124:801-812.

480 **35.** Holownia P, Owen EJ, Conway GS, Round J, Honour JW. Studies to confirm the  
481 source of 11 beta-hydroxyandrostenedione. J Steroid Biochem Mol Biol 1992; 41:875-  
482 880.

483 **36.** Torn S, Nokelainen P, Kurkela R, Pulkka A, Menjivar M, Ghosh S, Coca-Prados M,  
484 Peltoketo H, Isomaa V, Vihko P. Production, purification, and functional analysis of  
485 recombinant human and mouse 17beta-hydroxysteroid dehydrogenase type 7.  
486 Biochem Biophys Res Commun 2003; 305:37-45.

487 **37.** Jeppesen JV, Kristensen SG, Nielsen ME, Humaidan P, Dal Canto M, Fadini R,  
488 Schmidt KT, Ernst E, Yding Andersen C. LH-receptor gene expression in human  
489 granulosa and cumulus cells from antral and preovulatory follicles. J Clin Endocrinol  
490 Metab 2012; 97:E1524-1531.

491

492 **Figure Legends**

493 **Figure 1.** SF-1 induces HSD11B2 expression and 11-KT production in KGN cells. KGN cells  
494 were infected with adenoviruses expressing GFP or SF-1. Induction of HSD11B2 mRNA (A) and  
495 protein (B) by SF-1. A, mRNA expression of HSD11B2 gene was analyzed by Q-PCR and  
496 normalized to  $\beta$ -actin expression. Data represent the mean  $\pm$  SEM of at least three independent  
497 experiments. B, Western blot analyses were performed with antibodies against HSD11B2 and  
498 GAPDH using the same lysates. C, Induction of the enzymes for the synthesis of testosterone, 11-  
499 KT and E<sub>2</sub> was confirmed by Q-PCR. Data represent the mean  $\pm$  SEM of at least three  
500 independent experiments. D, 11-KT, testosterone and E<sub>2</sub> levels in each group were measured by  
501 EIA. Data represent the mean  $\pm$  SEM of at least three independent experiments. Differences  
502 between groups are indicated by \*\* $P < 0.01$ .

503 **Figure 2.** 11-KT production was induced by the ectopic expression of HSD11B2 in H295R cells.  
504 A, Expression of HSD11B2 in H295R cells. Expression of HSD11B2 was analyzed by Q-PCR  
505 and normalized to  $\beta$ -actin expression. The Kidney was used as positive controls. Q-PCR data  
506 represent the mean  $\pm$  SEM of at least three independent experiments. B-D, H295R cells were  
507 transfected with the empty vector or the expression vector for HSD11B2. B, Protein extracts from  
508 cells in each treatment were subjected to SDS-PAGE and western blot was performed using each  
509 antibody. C-D, Testosterone (C) and 11-KT (D) levels in each group were measured by EIA. Data  
510 represent the mean  $\pm$  SEM of at least three independent experiments. Differences between groups

511 are indicated by  $**P<0.01$ .

512 **Figure 3.** Expression of 11-KT synthetic enzymes in human gonads and plasma concentrations  
513 of 11-KT. A-B, Expression of CYP11B1 and HSD11B2 in human testis and ovary. A, mRNA  
514 levels of each gene analyzed by Q-PCR and normalized to  $\beta$ -actin expression. The adrenal gland  
515 and kidney were used as a positive control for each analysis. Q-PCR data represent the mean  $\pm$   
516 SEM of at least three independent samples. B, Western blot analyses were performed with  
517 antibodies against CYP11B1, HSD11B2, and GAPDH using lysates from each human tissue (20  
518  $\mu$ g protein). Western blot analysis is representative of the two experiments. C, Localization of  
519 CYP11B1 and HSD11B2 proteins in human gonads. Positive staining both for CYP11B1 and  
520 HSD11B2 was observed in testicular Leydig cells and ovarian theca cells. No staining was  
521 observed in control sections incubated with nonimmune serum. An, Antrum. D, Production of  
522 testosterone and 11-KT by human Leydig cells with or without 8br-cAMP for 48 h. Each androgen  
523 levels in each group were measured by EIA. Data represent the mean  $\pm$  SEM of at least three  
524 independent experiments. E-H, Levels of plasma testosterone, 11-KT and  $E_2$  in humans. Plasma  
525 testosterone (E), 11-KT (F) and  $E_2$  (G) levels in men and women were measured by LC-MS/MS.  
526 **In the box and whisker plots, boxes show 75th and 25th percentiles. Horizontal lines in the boxes**  
527 **represent the medians. Whiskers show the lowest values and the highest values.** Differences  
528 between groups are indicated by  $*P<0.05$  and  $**P<0.01$ . H, Comparison of plasma testosterone,

529 11-KT and E<sub>2</sub> levels within each sex. Data represent the mean ± SEM (n=10 men, n=10 women).

530 **Figure 4.** Activation of human AR-mediated transcription by DHT, testosterone, and 11-KT.

531 KGN cells were transfected with the ARE-Luc vector and the human AR-expression vector. At

532 24 h post-transfection, cells were incubated with or without increasing concentrations of each

533 androgen for 24 h. Data represent the mean ± SEM of at least four independent experiments.

534 **Figure 5.** Comparison of ER-mediated transactivation by E<sub>2</sub>, DHT, testosterone, and 11-KT in

535 MCF-7 cells. MCF-7 cells were transfected with the ERE-Luc reporter vector. At 24 h post-

536 transfection, increasing concentrations of each steroid hormones were added with (A) or without

537 (B) the aromatase inhibitor fadrozole for 24 h. Data represent the mean ± SEM of at least four

538 independent experiments.

539 **Figure 6.** The effects of each androgen on the proliferation in parental and AR-introduced

540 MCF-7 cells. A-C, The effects of each steroid hormone on the proliferation of parental MCF-7

541 cells. A, Cells were cultured with or without each steroid hormones at various concentrations for

542 6 days. Data represent the mean ± SEM of three independent experiments. Values marked by

543 different letters are significantly different (P<0.05). B–C, Effects of the aromatase inhibitor

544 fadrozole (B) and the ER-antagonist fulvestrant (C) at 1 μM on testosterone-induced (10<sup>-7</sup>M) cell


545 proliferation. Data represent the mean ± SEM of three independent experiments. Values marked

546 by different letters are significantly different (P<0.05). D-E, Cell growth inhibition by androgens




547 in AR-introduced MCF-7 cells. D, Western blot analyses were performed with the antibodies  
548 against AR and GAPDH using lysates derived from parental and AR-introduced MCF-7 cells. E,  
549 The effects of each androgen on the inhibition of cell growth in AR-introduced MCF-7 cells. Cells  
550 were cultured with or without each androgen at  $10^{-7}$ M for 9 days. Data represent the mean  $\pm$  SEM  
551 of five independent experiments. Values marked by different letters are significantly different  
552 ( $P < 0.05$ ).





**Figure 1**




**Figure 2**



**Figure 3**



**Figure 3 (continued)**



**H**

	Men	Women
testosterone (pg/ml)	4548 ± 625	225 ± 26
11-KT (pg/ml)	234 ± 47	250 ± 66
E <sub>2</sub> (pg/ml)	23 ± 4.3	54 ± 14.2

Figure 4






Figure 5






A



B



**Figure 6**






Supplemental Table 1. Primers used in each experiment.

<b>PCR primers</b>	<b>Forward primers</b>	<b>Reverse primers</b>
<b>RT-PCR</b> HSD17B5	F-atggcagtggaagagaga	R-tctagcaattactccggtga
<b>qPCR</b> CYP17A1	F-gtggagaccaccacctctgt	R-gctgaaaccacattctggt
CYP11B1	F-tgaatccagaagtgctgctg	R-gcagcaccttcttctcagg
HSD11B2	F-gacctgaccaaacagaaggaga	R-ccgcatcagcaactacttca
CYP19A1	F-atgaagctctgcaggccc	R-tcaacacgtccacatagccc


**Supplemental table 2.** Genes induced by Overexpression of SF-1 in Human Ovarian Granulosa Cell Tumor-derived KGN Cells.

Gene Symbol	Gene Name	Fold Change
PLIN1	perilipin	1061.9
GSTA1	glutathione S-transferase alpha 1	554.0
AADAC	arylacetamide deacetylase (esterase)	551.0
HSD11B2	hydroxysteroid (11-beta) dehydrogenase 2	429.5
HSD3B2	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	397.8
AOC3	amine oxidase, copper containing 3 (vascular adhesion protein 1)	341.8
LBP	lipopolysaccharide binding protein	283.5
CYP3A4	cytochrome P450, family 3, subfamily A, polypeptide 4	281.7
DLK1	delta-like 1 homolog (Drosophila)	196.5
CYP17A1	cytochrome P450, family 17, subfamily A, polypeptide 1	153.6
ITIH3	inter-alpha (globulin) inhibitor H3	131.1
KCNK3	potassium channel, subfamily K, member 3	112.4
GSTA3	glutathione S-transferase alpha 3	109.9
HES6	hairy and enhancer of split 6 (Drosophila)	99.9
LBP	lipopolysaccharide binding protein	94.9
RASGEF1A	RasGEF domain family, member 1A	94.8
APOA1	apolipoprotein A-I	80.3
CXCL14	chemokine (C-X-C motif) ligand 14	72.0
RBP4	retinol binding protein 4, plasma	56.6
CYP19A1	cytochrome P450, family 19, subfamily A, polypeptide 1	51.6
CYP11B1	cytochrome P450, family 11, subfamily B, polypeptide 1	46.9
SLC13A2	solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2	39.2
LOC731779	hypothetical protein LOC731779	34.5
CYP11A1	cytochrome P450, family 11, subfamily A, polypeptide 1	33.4





**Supplemental Figure 1.**

The enzymes and pathways for the synthesis of 11-KT. The enzymes, indicated by bold letters, represent genes that can be induced by SF-1 introduction in DNA microarray analyses.



**Supplemental Figure 2.**

Expression of the enzymes for the synthesis of 11-OHT in H295R and Adrenal. mRNA expression of each gene was analyzed by RT-PCR.



**Supplemental Figure 3.**

A, Expression of StAR, the enzymes for the synthesis of 11-KT and LH receptor in Leydig cells and testis. mRNA expression of each gene was analyzed by RT-PCR. B, Production of progesterone by Leydig cells with or without cAMP were measured by EIA.